Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin for TyG index in atherosclerotic coronary artery disease
IRCT20250315065073N1Phase 3Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, double-blind trial of dapagliflozin in coronary arteriosclerosis (2 arms), sponsored by Tehran University of Medical Sciences. Primary endpoint: Triglyceride Glucose Index (TyG index). Started May 2025; status: completed.
02
Drugs
dapagliflozin
03
Conditions
coronary arteriosclerosis
Beyond the preview
Go deeper on IRCT20250315065073N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20250315065073N1.